Navigation Links
Mirati Therapeutics Reports Second Quarter 2014 Financial Results and Provides Business Update
Date:8/8/2014

SAN DIEGO, Aug. 8, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today reported financial results for the second quarter ended June 30, 2014 and provided an update on its drug development programs.

"In the past quarter we expanded the scope of our clinical programs, identified compelling patient selection strategies targeting driver mutations, and positioned the company to obtain initial data by the end of the year from multiple proof of concept studies," said Charles M. Baum, M.D., Ph.D., president and CEO of Mirati. "We have made significant strides in executing on our precision oncology strategy and are looking forward to achieving significant milestones within each of our programs."

Second Quarter 2014 Business UpdateMGCD265

  • Phase 1 safety and dose escalation study ongoing
  • Planning to initiate expansion cohorts with a goal of obtaining initial proof of concept data by the end of 2014 in patients who have genetic alterations in Met and Axl
  • MGCD516

  • Phase 1 safety and dose escalation study initiated
  • On track to identify a Phase 2 dose by the end of 2014
  • Mocetinostat

  • Secured orphan drug designation for mocetinostat in myelodysplastic syndromes; orphan applications for bladder cancer and diffuse large b-cell lymphoma (DLBCL) have been submitted
  • The mocetinostat Phase 2 dose confirmation trial is ongoing and the mocetinostat Phase 2 trials in bladder cancer and DLBCL will commence in Q3 with the goal of obtaining initial proof of concept data by the end of 2014
  • Second Quarter 2014 Financial Results Cash, cash equivalents, and short-term investments were $47.4 million at June 30, 2014, compared to $62.1 million at December 31, 2013.

    Research and development expenditures for the second quarter of 2014 were $7.2 million, compared to $4.5 million for the
    '/>"/>

    SOURCE Mirati Therapeutics, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Mirati Presents Clinical Response Results of Mocetinostat in Combination with Azacitidine as a Treatment for MDS
    2. Updated Presentation Time: Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    3. Mirati Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
    4. Mirati Therapeutics Reports Third Quarter 2013 Financial Results
    5. Mirati Therapeutics Prices Public Offering Of Common Stock
    6. Mast Therapeutics To Present At The Canaccord Genuity 34th Annual Growth Conference On August 14th
    7. Orexigen Therapeutics Reports Corporate and Financial Results for the Second Quarter Ended June 30, 2014
    8. PTC Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update
    9. Pivotal Therapeutics To Explore Potential Commercial Partnership Opportunities in China
    10. Relmada Therapeutics, Inc. Completes Name Change and Announces New Ticker
    11. PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... In response to urgent requests from the Deputy Minister ... Leone , Direct Relief delivered two 10-bed medical tents ... of local health workers who contract Ebola while fighting the ... center was constructed for foreign health care workers who may ... local Sierra Leonean health workers. With ...
    (Date:12/22/2014)... , Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), ... CytoSorb® blood purification technology to help fight deadly ... 28 countries worldwide, today announced the appointment of ... FACS, as its Senior Vice President of Clinical ... Dr. Di Russo is an accomplished ...
    (Date:12/22/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has ... Glucose Market" report to their offering. ... insight focuses on the developments in the self-monitoring blood ... . Reimbursement analysis and the effects of competitive bidding ... 73 SMBG meters have been performed, based on the ...
    Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
    ... Pfizer Inc. (NYSE: PFE ) have launched ... therapies for Duchenne muscular dystrophy (DMD). At the heart ... exchange of expertise that brings the respective strengths of ... hold promise for benefitting DMD patients in the future. ...
    ... ANN ARBOR, Mich., Nov. 9, 2011 ... company developing and commercializing innovative diagnostics and ... CardioDefender diagnostic system.  CardioDefender is the first ... to provide physicians and patients with hospital-quality ...
    Cached Medicine Technology:Children's Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics 2Children's Hospital Boston and Pfizer Enter Into Novel Collaborative Research Agreement for Muscular Dystrophy Therapeutics 3Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 2Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 3Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 4Everist Genomics to Launch CardioDefender: World's Only Mobile ECG System that Delivers Real-time, Beat-by-beat, Quantitative Heart Monitoring Data to Physicians 5
    (Date:12/26/2014)... 26, 2014 India Network Foundation, a ... the USA, announced today a new version of “ ... choosing the right plan for their visiting parents. The ... of the selection process when choosing an insurance plan ... with only a few clicks. Many elderly Asian Indian ...
    (Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
    (Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – ... current treatment landscape, unmet needs, current pipeline and commercial ... anti-cancer drug which is typically used for treating colorectal ... for treating gastric cancer and pancreatic cancer. TS-1 is ... was first approved in 1999 in Japan for the ...
    (Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
    (Date:12/25/2014)... Helen Harris’ RP (Retinitis Pigmentosa) International founder ... an 8 year battle with breast cancer. , ... her home in Woodland Hills California after an 8 ... , As the founder and volunteer President of ... championed many of today's greatest breakthroughs in restoring and ...
    Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
    ... in Australia have developed a process for rapidly and efficiently ... parts, potentially allowing doctors //to do blood tests without sending ... the same principle that causes tea leaves to accumulate at ... phenomenon first explained by Einstein in the 1920s. ...
    ... a frozen embryo at the time of the hurricane Katrina floods, ... ,The baby has been named Noah, after the great survivor. Noah ... frozen in liquid nitrogen when floods hit the hospital. ... third as the hurricane waters entered the hospital and rose till ...
    ... have created a new method for fighting Leukemia. ... of a novel agent that triggers programmed cell death, ... for fighting leukemia and other malignancies. ,The ... cancer cells. The process is regulated by a large ...
    ... has demonstrated China’s renewed commitment to check animal diseases. China ... dollars) to control and prevent animal diseases. // ,The ... bird flu, foot-and-mouth disease, by 2015 and possibly even root ... will enable about 5.66 billion yuan and the remaining amount ...
    ... designed a vitamin D tablet Asentar, to treat advanced prostate ... slow down certain cancers. But consuming natural levels// of the ... levels of vitamin D 50-100 times higher than normal and ... prostate cancer along with chemotherapy drugs. ,Asentar is ...
    ... death in the U.S.; more than 30,000 Americans are expected ... cancer is an extremely difficult cancer to treat and little ... in pancreatic cancer is cigarette smoking; other links have been ... a new study, researchers at the Harvard School of Public ...
    Cached Medicine News:Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2Health News:New Method For Fighting Leukemia 2Health News:Vitamin D Tablets to Cure Prostate Cancer 2Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2
    ... percutaneously to direct a .038 ... guide to a specific renal ... an inner stainless steel braid ... the catheter shaft. Supplied sterile ...
    Supplied sterile in peel-open packages. Intended for one-time use....
    Supplied sterile in peel-open packages. Intended for one-time use....
    Used when establishing a percutaneous tract for nephrostomy drainage. The wire guide has an extra stiff shaft and a gradual transition to a very flexible tip. Supplied sterile in peel-open packages. ...
    Medicine Products: